摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[[2-[(1-Aminoisoquinolin-6-yl)amino]-2-(3-ethoxy-4-propan-2-yloxyphenyl)acetyl]sulfamoyl]benzamide | 745019-76-5

中文名称
——
中文别名
——
英文名称
3-[[2-[(1-Aminoisoquinolin-6-yl)amino]-2-(3-ethoxy-4-propan-2-yloxyphenyl)acetyl]sulfamoyl]benzamide
英文别名
——
3-[[2-[(1-Aminoisoquinolin-6-yl)amino]-2-(3-ethoxy-4-propan-2-yloxyphenyl)acetyl]sulfamoyl]benzamide化学式
CAS
745019-76-5
化学式
C29H31N5O6S
mdl
——
分子量
577.661
InChiKey
XMYBUOHBAIWKLS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    41
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    184
  • 氢给体数:
    4
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS<br/>[FR] DERIVES DE PHENYLGLYCINE UTILES EN TANT QU'INHIBITEURS DE SERINE PROTEASE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2004072101A2
    公开(公告)日:2004-08-26
    Compounds having the formula (I), or a stereoisomer or pharmaceutically-acceptable salt, or hydrate thereof, are useful as factor VIIa inhibitors, wherein X is NR6S(O)pR16; W is hydrogen or (CR7R8)q­- W1; W1 is hydrogen or a bond with R6; Z is a 5-membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, a 9 to 10 membered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R1, R2, R3 , R6, R7, and R16 are as defined in the specification.
  • Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors
    作者:Peter W. Glunz、Xiaojun Zhang、Yan Zou、Indawati Delucca、Alexandra H. Nirschl、Xuhong Cheng、Carolyn A. Weigelt、Daniel L. Cheney、Anzhi Wei、Rushith Anumula、Joseph M. Luettgen、Alan R. Rendina、Mark Harpel、Gang Luo、Robert Knabb、Pancras C. Wong、Ruth R. Wexler、E. Scott Priestley
    DOI:10.1016/j.bmcl.2013.06.027
    日期:2013.9
    Aminoisoquinoline and isoquinoline groups have successfully replaced the more basic P1 benzamidine group of an acylsulfonamide factor Vila inhibitor. Inhibitory activity was optimized by the identification of additional hydrophobic and hydrophilic P' binding interactions. The molecular details of these interactions were elucidated by X-ray crystallography and molecular modeling. We also show that decreasing the basicity of the P1 group results in improved oral bioavailability in this chemotype. (C) 2013 Elsevier Ltd. All rights reserved.
查看更多